Overview

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate two different ultraviolet (UV) dosing regimens for corneal collagen cross linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive surgery ectasia.
Phase:
Phase 2
Details
Lead Sponsor:
Mercy Center for Corrective Eye Surgery
Treatments:
Riboflavin